東北大学研究者紹介

研究者詳細

ホーム

日本語 English

サトフカ　ヒロユキ

里深　博幸

Hiroyuki Satofuka

所属

大学院医学系研究科　医科学専攻　生体機能学講座（抗体創薬学分野）

職名

助教

学位

博士(工学) （京都大学大学院）

researchmap

https://researchmap.jp/H.Satofuka

J-GLOBAL ID

201801009437399552

e-Rad 研究者番号

60373312

経歴 8

2024年4月～継続中

東北大学　大学院医学研究科抗体創薬学分野　助教
2017年8月～ 2024年3月

鳥取大学　准教授
2017年3月～ 2017年7月

鳥取大学　プロジェクト研究員
2012年11月～ 2017年2月

株式会社オーダーメードメディカルリサーチ　主席研究員
2004年11月～ 2012年5月

株式会社バイオマトリックス研究所　主任研究員兼部長代理
2004年4月～ 2004年10月

理化学研究所　基礎科学特別研究員
2001年5月～ 2004年3月

理化学研究所
2000年4月～ 2001年5月

北陸先端科学技術大学院大学　材料科学　CREST研究員

︎全件表示 ︎最初の5件までを表示

学歴 3

京都大学大学院　工学研究科　合成・生物化学

1998年4月～ 2001年3月
大阪大学大学院　工学研究科　応用生物工学

1996年4月～ 1998年3月
広島大学　工学部　第三類・化学

1992年4月～ 1996年3月

研究キーワード 2

タンパク質工学
抗体工学

研究分野 3

ライフサイエンス / 免疫学 /
ライフサイエンス / 応用生物化学 /
ライフサイエンス / 細胞生物学 /

受賞 1

ポスター優秀賞

2022年12月　第１回日本抗体学会学術大会　完全ヒト抗体産生ラット(TC-mAbラット)の作製と抗体レパトアの解析

論文 33

Two stress-responsive kinases suppress ferroptosis by activating antioxidant programs under mild oxidative stress. 国際誌

Yumiko Fujikawa, Hirotatsu Imai, Tetsuo Onuki, Kouji Hoshino, Marco A De Velasco, Kazuhiko Matsuo, Hitomi Kurosawa, Kyoko Aoyagi, Hiroko Hirose, Yoshie Nakamura, Akiko Uchiyama, Kae Suzuki, Mariko Mizuguchi, Hidehisa Takahashi, Hiroyuki Osada, Noritaka Kagaya, Kazuo Shin-Ya, Hiroyuki Satofuka, Yukinari Kato, Hidehito Kuroyanagi, Daisuke Utsumi, Kenzo Takahashi, Takashi Nakayama, Hirotsugu Uemura, Hiroji Uemura, Minoru Yoshida, Shigeo Ohno, Akio Yamashita

Signal transduction and targeted therapy　11　(1)　2026年8月3日

DOI： 10.1038/s41392-026-02892-1 　

詳細を見る詳細を閉じる

Cancer cells maintain chronically elevated levels of reactive oxygen species (ROS) while relying on robust antioxidant programs to preserve redox homeostasis and viability. Although therapeutic strategies that disrupt this balance to induce lethal oxidative stress and ferroptosis have emerged as promising anticancer approaches, the upstream signaling mechanisms that constrain ROS accumulation under physiologically relevant stress conditions remain incompletely understood. Here, we identify the stress-responsive kinases SMG1 and DNA-dependent protein kinase (DNA-PK) as functionally redundant regulators of redox homeostasis and ferroptosis resistance. Genetic or pharmacological inhibition of either kinase triggers ferroptotic cell death, accompanied by marked accumulation of total ROS, ferrous iron, and lipid hydroperoxides. Mechanistically, under mild oxidative stress, SMG1 and DNA-PK cooperatively phosphorylate the central antioxidant transcription factor NRF2 at serine 13 and serine 40, weakening its interaction with the negative regulator KEAP1 and promoting NRF2 accumulation and transcriptional activation. Transcriptomic profiling of de novo mRNAs revealed that inhibition of either kinase is sufficient to suppress NRF2-driven antioxidant gene expression. In contrast, excessive oxidative stress overrides this pro-survival pathway and redirects signaling toward anti-survival responses mediated by ATF4, ATM-CHK2, and JNK/p38 pathways. Collectively, these findings uncover a previously unrecognized SMG1/DNA-PK-NRF2 signaling axis that functions as a redox stress-intensity-dependent switch governing cell fate decisions between antioxidant adaptation and ferroptotic death. Targeting this axis may represent a promising therapeutic strategy for cancer treatment.
Development of a specific anti-human EphA3 monoclonal antibody, Ea3Mab-20, for flow cytometry 国際誌査読有り

Hiroyuki Satofuka, Hiroyuki Suzuki, Miu Hirose, Keisuke Shinoda, Takuya Nakamura, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato

Biochemistry and Biophysics Reports　43　102130-102130　2025年9月

DOI： 10.1016/j.bbrep.2025.102130 　

詳細を見る詳細を閉じる

Erythropoietin-producing hepatocellular (Eph) receptor A3 (EphA3) is a member of the Eph receptor family, which binds to its respective ligands, ephrins. These interactions are essential for normal development and tissue homeostasis. Dysregulation of EphA3 has been reported to be associated with human hematopoietic malignancies, making it a promising target for therapy and diagnosis. Due to the high similarity of the extracellular domain among Eph receptors (more than 33% amino acid identity), generating highly specific monoclonal antibodies (mAbs) is crucial. We developed anti-human EphA3 mAbs in this study using the Cell-Based Immunization and Screening (CBIS) method. Among them, the clone Ea3Mab-20 (IgG1, kappa) exhibited high affinity and specificity in flow cytometry. The dissociation constant values of Ea3Mab-20 for CHO/EphA3 and Jurkat cells were determined to be 9.0 ± 0.3 × 10-9 M and 1.4 ± 0.1 × 10-9 M, respectively. Ea3Mab-20 showed no cross-reactivity with other Eph receptors in flow cytometry. Furthermore, Ea3Mab-20 demonstrated the suitability for detecting formalin-fixed paraffin-embedded cell samples in immunohistochemistry. Therefore, Ea3Mab-20 is valuable mAb for basic research and is expected to contribute to the clinical application of mAb for cancer therapy and diagnosis.
Development of Anti-Human Cadherin-26 Monoclonal Antibody, Ca₂₆Mab-6, for Flow Cytometry 国際誌

Hiroyuki Satofuka, Hiroyuki Suzuki, Mika K. Kaneko, Yukinari Kato

Monoclonal antibodies in immunodiagnosis and immunotherapy　45　(3)　25-33　2025年8月12日

DOI： 10.20944/preprints202508.0774.v1 　

詳細を見る詳細を閉じる

Cadherin 26 (CDH26) is a recently identified member of the cadherin superfamily. Although CDH26 gene expression has been reported in association with allergic inflammatory responses, the protein expression levels and the signaling pathways mediated through its interactions with other proteins remain poorly understood. This is primarily due to the lack of monoclonal antibodies (mAbs) that can recognize the intact, cell surface-expressed form of CDH26. In this study, we developed an antihuman CDH26 mAb, Ca26Mab-6 (IgM, kappa), using the Cell-Based Immunization and Screening (CBIS) method. Ca26Mab-6 demonstrated high sensitivity and specificity for CDH26 in flow cytometry and did not bind to Chinese hamster ovary (CHO)-K1 cells, which overexpress any of the other type I or type II cadherins. Ca26Mab-6 successfully detected endogenous CDH26 protein expression in HepG2, U-87 MG, MCF7, and 293FT cells. The apparent dissociation constant of Ca26Mab-6 was determined to be 9.8 ± 4.8 × 10-9 M for CDH26-overexpressed CHO-K1 (CHO/CDH26) cells and 3.6 ± 1.0 × 10-7 M for HepG2 cells. The detection of CDH26 expression in cancer cells may offer new insights into the potential relationship between inflammatory responses and malignant transformation. Therefore, Ca26Mab-6, developed using the CBIS method, is expected to facilitate functional studies of CDH26 and contribute to the development of CDH26-targeted antibody-based therapies.
Development of an anti-human EphA2 monoclonal antibody Ea2Mab-7 for multiple applications 国際誌査読有り

Hiroyuki Satofuka, Hiroyuki Suzuki, Tomohiro Tanaka, Guanjie Li, Mika K. Kaneko, Yukinari Kato

Biochemistry and Biophysics Reports　42　101998-101998　2025年6月

DOI： 10.1016/j.bbrep.2025.101998 　

詳細を見る詳細を閉じる

Ephrin type A receptor 2 (EphA2) binds to membrane-bound ligands, ephrin A1, A2, and A5, eliciting bidirectional signaling. This signaling regulates many physiological processes, such as tissue development, homeostasis, and regeneration. The dysregulation of the EphA2-ephrins axis contributes to various diseases, including cancers. The high expression of EphA2 is observed in various cancers, which promotes cancer malignancy, whereas its levels are relatively low in most normal adult tissues. Therefore, EphA2 is a promising target for cancer therapy. We developed anti-human EphA2 monoclonal antibodies in this study using the Cell-Based Immunization and Screening method. Among them, a clone Ea2Mab-7 (IgG1, κ) exhibited a high affinity and sensitivity in flow cytometry. The dissociation constant values of Ea2Mab-7 for CHO/EphA2 and MDA-MB-231 cells were determined as 6.2 ± 1.3 × 10-9 M and 1.6 ± 0.4 × 10-9 M, respectively. Furthermore, Ea2Mab-7 can detect endogenous EphA2 in Western blot and immunohistochemistry. Therefore, the Ea2Mab-7 is highly versatile for basic research and is expected to contribute to clinical applications, such as antibody therapy and tumor diagnosis.
Ea₃Mab-20: A Specific Anti-Human EphA3 Monoclonal Antibody for Flow Cytometry

Hiroyuki Satofuka, Hiroyuki Suzuki, Miu Hirose, Keisuke Shinoda, Takuya Nakamura, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato

2025年4月7日

DOI： 10.20944/preprints202504.0524.v1 　
A novel Anti-Mouse CCR7 Monoclonal Antibody, C7Mab-7, Demonstrates High Sensitivity in Flow Cytometry, Western Blot, and Immunohistochemistry 国際誌

Hiroyuki Satofuka, Hiroyuki Suzuki, Tomohiro Tanaka, Rena Ubukata, Miu Hirose, Haruto Yamamoto, Yu Kaneko, Shiori Fujisawa, Guanjie Li, Mika K Kaneko, Yukinari Kato

Biochemistry and biophysics reports　41　101948-101948　2024年11月26日

DOI： 10.20944/preprints202411.1959.v1 　

詳細を見る詳細を閉じる

C-C chemokine receptor type 7 (CCR7) is a member of the G protein-coupled receptor family and functions as a lymph node-homing receptor for immune cells. Upon ligand binding, CCR7 promotes the migration of immune cells to secondary lymphoid organs. In cancers, CCR7 has been revealed as a critical molecule in lymph node metastasis. Consequently, anti-CCR7 monoclonal antibodies (mAbs) have been developed as cancer therapeutic agents. In this study, we established an anti-mouse CCR7 (mCCR7) mAb, C7Mab-7 (rat IgG1, kappa) using the Cell-Based Immunization and Screening (CBIS) method. C7Mab-7 demonstrated high sensitivity in flow cytometry. The dissociation constant (K D) value of C7Mab-7 was determined to be 2.5 × 10⁻⁹ M for mCCR7-overexpressed Chinese hamster ovary-K1 (CHO/mCCR7) cells. Furthermore, C7Mab-7 detected mCCR7 with high sensitivity in western blot and immunohistochemistry. C7Mab-7, developed by the CBIS method, accelerates the development of CCR7-targeted antibody therapies and cancer diagnostics.
Developing a workflow for the isolation of hybridoma cells producing fully human antigen-specific antibodies using a surface IgG detection method. 国際誌査読有り

Hiroyuki Satofuka, Yayan Wang, Hiroshi Tanaka, Kei Hiramatsu, Kayoko Morimoto, Haruka Takayama, Haochen Tu, Yu Qiao, Satoru Ito, Xu Gao, Mitsuo Oshimura, Yasuhiro Kazuki

Scientific reports　14　(1)　23138-23138　2024年10月4日

DOI： 10.1038/s41598-024-73770-5 　

詳細を見る詳細を閉じる

The antigen-mediated B cell isolation method, based on the detection of surface IgG (sIgG), has increased the efficiency of therapeutic antibody (Ab) discovery. However, the reduction in sIgG expression on B cells during plasma cell differentiation presents challenges as it enables Ab production from only a small subset of B cells (e.g., memory B cells). The present study aimed to addressed this problem by developing a workflow to isolate human-IgG-secreting hybridoma cells produced by cell fusion, the majority of which express sIgG. We showed that our sIgG-based antigen-coated bead separation method efficiently enriched hybridoma cells expressing antigen-specific Abs with a yield of 83.5% (from the cell fusion pool) and a positive rate of 73.2%. Furthermore, because the separation could be performed after only a short (1-2-day) culture period following cell fusion, diverse hybridoma clones could be obtained, minimizing clonal selection and the incidence of duplicates. Given that the expression of membrane-bound IgG and sIgG are regulated by different splicing mechanisms, we speculate that the cell fusion step potentially attenuated the suppression of human sIgG expression. Overall, our proposed method is expected to markedly improve the efficiency of therapeutic Ab candidate production, which will have important clinical implications.
Comparative analysis of trans-chromosomic rodent models reveals improved somatic hypermutation and class-switch recombination in rats

Hiroyuki Satofuka, Satoshi Abe, Takashi Moriwaki, Akane Okada, Kanako Kazuki, Shusei Hamamichi, Masaharu Hiratsuka, Masumi Hirabayashi, Kazuomi Nakamura, Tetsushi Sakuma, Takashi Yamamoto, Yoshihiro Baba, Kazuma Tomizuka, Yasuhiro Kazuki

2024年8月26日

DOI： 10.1101/2024.08.26.609625 　
Treatment of CHO cells with Taxol and reversine improves micronucleation and microcell-mediated chromosome transfer efficiency 国際誌査読有り

Narumi Uno, Hiroyuki Satofuka, Hitomaru Miyamoto, Kazuhisa Honma, Teruhiko Suzuki, Kyotaro Yamazaki, Ryota Ito, Takashi Moriwaki, Shusei Hamamichi, Kazuma Tomizuka, Mitsuo Oshimura, Yasuhiro Kazuki

Molecular Therapy - Nucleic Acids　33　391-403　2023年7月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.omtn.2023.07.002 　

ISSN：2162-2531

詳細を見る詳細を閉じる

Microcell-mediated chromosome transfer is an attractive technique for transferring chromosomes from donor cells to recipient cells and has enabled the generation of cell lines and humanized animal models that contain megabase-sized gene(s). However, improvements in chromosomal transfer efficiency are still needed to accelerate the production of these cells and animals. The chromosomal transfer protocol consists of micronucleation, microcell formation, and fusion of donor cells with recipient cells. We found that the combination of Taxol (paclitaxel) and reversine rather than the conventional reagent colcemid resulted in highly efficient micronucleation and substantially improved chromosomal transfer efficiency from Chinese hamster ovary donor cells to HT1080 and NIH3T3 recipient cells by up to 18.3- and 4.9-fold, respectively. Furthermore, chromosome transfer efficiency to human induced pluripotent stem cells, which rarely occurred with colcemid, was also clearly improved after Taxol and reversine treatment. These results might be related to Taxol increasing the number of spindle poles, leading to multinucleation and delaying mitosis, and reversine inducing mitotic slippage and decreasing the duration of mitosis. Here, we demonstrated that an alternative optimized protocol improved chromosome transfer efficiency into various cell lines. These data advance chromosomal engineering technology and the use of human artificial chromosomes in genetic and regenerative medical research.
Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate 国際誌査読有り

Hiroyuki Satofuka, Yayan Wang, Kyotaro Yamazaki, Shusei Hamamichi, Takeshi Fukuhara, Abdur Rafique, Nana Osako, Iori Kanazawa, Takeshi Endo, Naomi Miyake, Kazuhisa Honma, Yuichi Nagashima, Genki Hichiwa, Kazuto Shimoya, Satoshi Abe, Takashi Moriwaki, Yasufumi Murakami, Xu Gao, Hiroyuki Kugoh, Mitsuo Oshimura, Yuji Ito, Yasuhiro Kazuki

Scientific Reports　13　(1)　4225-4225　2023年3月14日
出版者・発行元： Springer Science and Business Media LLC
DOI： 10.1038/s41598-023-31263-x 　

eISSN：2045-2322

詳細を見る詳細を閉じる

Abstract We previously generated fully human antibody-producing TC-mAb mice for obtaining potential therapeutic monoclonal antibodies (mAbs). In this study, we investigated 377 clones of fully human mAbs against a tumor antigen, epithelial cell adhesion molecule (EpCAM), to determine their antigen binding properties. We revealed that a wide variety of mAbs against EpCAM can be obtained from TC-mAb mice by the combination of epitope mapping analysis of mAbs to EpCAM and native conformational recognition analysis. Analysis of 72 mAbs reacting with the native form of EpCAM indicated that the EpCL region (amino acids 24–80) is more antigenic than the EpRE region (81–265), consistent with numerous previous studies. To evaluate the potential of mAbs against antibody–drug conjugates, mAbs were directly labeled with DM1, a maytansine derivative, using an affinity peptide-based chemical conjugation (CCAP) method. The cytotoxicity of the conjugates against a human colon cancer cell line could be clearly detected with high-affinity as well as low-affinity mAbs by the CCAP method, suggesting the advantage of this method. Thus, this study demonstrated that TC-mAb mice can provide a wide variety of antibodies and revealed an effective way of identifying candidates for fully human ADC therapeutics.
Efficient human-like antibody repertoire and hybridoma production in trans-chromosomic mice carrying megabase-sized human immunoglobulin loci 国際誌査読有り

Hiroyuki Satofuka, Satoshi Abe, Takashi Moriwaki, Akane Okada, Kanako Kazuki, Hiroshi Tanaka, Kyotaro Yamazaki, Genki Hichiwa, Kayoko Morimoto, Haruka Takayama, Yuji Nakayama, Shinya Hatano, Yutaro Yada, Yasufumi Murakami, Yoshihiro Baba, Mitsuo Oshimura, Kazuma Tomizuka, Yasuhiro Kazuki

Nature Communications　13　(1)　1841-1841　2022年4月
出版者・発行元： Springer Science and Business Media LLC
DOI： 10.1038/s41467-022-29421-2 　

eISSN：2041-1723

詳細を見る詳細を閉じる

Abstract Trans-chromosomic (Tc) mice carrying mini-chromosomes with megabase-sized human immunoglobulin (Ig) loci have contributed to the development of fully human therapeutic monoclonal antibodies, but mitotic instability of human mini-chromosomes in mice may limit the efficiency of hybridoma production. Here, we establish human antibody-producing Tc mice (TC-mAb mice) that stably maintain a mouse-derived, engineered chromosome containing the entire human Ig heavy and kappa chain loci in a mouse Ig-knockout background. Comprehensive, high-throughput DNA sequencing shows that the human Ig repertoire, including variable gene usage, is well recapitulated in TC-mAb mice. Despite slightly altered B cell development and a delayed immune response, TC-mAb mice have more subsets of antigen-specific plasmablast and plasma cells than wild-type mice, leading to efficient hybridoma production. Our results thus suggest that TC-mAb mice offer a valuable platform for obtaining fully human therapeutic antibodies, and a useful model for elucidating the regulation of human Ig repertoire formation.
A SARS-CoV-2 Antibody Broadly Neutralizes SARS-related Coronaviruses and Variants by Coordinated Recognition of a Virus Vulnerable Site 国際誌査読有り

Taishi Onodera, Shunsuke Kita, Yu Adachi, Saya Moriyama, Akihiko Sato, Takao Nomura, Shuhei Sakakibara, Takeshi Inoue, Takashi Tadokoro, Yuki Anraku, Kohei Yumoto, Cong Tian, Hideo Fukuhara, Michihito Sasaki, Yasuko Orba, Nozomi Shiwa, Naoko Iwata, Noriyo Nagata, Tateki Suzuki, Jiei Sasaki, Tsuyoshi Sekizuka, Keisuke Tonouchi, Lin Sun, Shuetsu Fukushi, Hiroyuki Satofuka, Yasuhiro Kazuki, Mitsuo Oshimura, Tomohiro Kurosaki, Makoto Kuroda, Yoshiharu Matsuura, Tadaki Suzuki, Hirofumi Sawa, Takao Hashiguchi, Katsumi Maenaka, Yoshimasa Takahashi

Immunity　54　(10)　2385-2398　2021年8月
出版者・発行元： Elsevier BV
DOI： 10.1016/j.immuni.2021.08.025 　

ISSN：1074-7613

詳細を見る詳細を閉じる

Potent neutralizing SARS-CoV-2 antibodies often target the spike protein receptor-binding site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple sarbecoviruses and drifted viruses. Here, using humanized mice, we identified an RBS antibody with a germline VH gene that potently neutralized SARS-related coronaviruses, including SARS-CoV and SARS-CoV-2 variants. X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved sites and the light chain of RBS with a binding angle mimicking the angiotensin-converting enzyme 2 (ACE2) receptor. The minimum footprints in the hypervariable region of RBS contributed to the breadth of neutralization, which was enhanced by immunoglobulin G3 (IgG3) class switching. The coordinated binding resulted in broad neutralization of SARS-CoV and emerging SARS-CoV-2 variants of concern. Low-dose therapeutic antibody treatment in hamsters reduced the virus titers and morbidity during SARS-CoV-2 challenge. The structural basis for broad neutralizing activity may inform the design of a broad spectrum of therapeutics and vaccines.
Immunization method for multi-pass membrane proteins using highly metastatic cell lines 国際誌査読有り

Hiroyuki Satofuka, Yoko Okabe, Yuki Takano, Takahiko Utsugi, Masaya Ohtsu, Yasufumi Murakami

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS　450　(1)　99-104　2014年7月

DOI： 10.1016/j.bbrc.2014.05.065 　

ISSN：0006-291X

eISSN：1090-2104
Ea₁₀Mab-3: A Novel Anti-EphA10 Monoclonal Antibody for Flow Cytometry

Keisuke Shinoda, Hiroyuki Suzuki, Takuya Nakamura, Yukari Ogura, Reina Ito, Hiroyuki Satofuka, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato

2026年6月4日

DOI： 10.20944/preprints202606.0383.v1 　
Chimeric Anti-Glypican 1 Antibodies Exert Antitumor Activities in Xenograft Models of Lung and Pancreatic Cancers 国際誌

Haruto Yamamoto, Hiroyuki Suzuki, Tomokazu Ohishi, Hiroyuki Satofuka, Mika K. Kaneko, Yukinari Kato

International Journal of Molecular Sciences　27　(10)　2026年5月8日

DOI： 10.3390/ijms27104181 　

詳細を見る詳細を閉じる

Glypican-1 (GPC1) has emerged as a critical mediator of malignant tumor progression. GPC1 plays essential roles in regulating various signaling pathways involved in tumor cell proliferation, invasiveness, and tumorigenesis. Overexpression of GPC1 in tumors mediates oncogenic transformation, epithelial-to-mesenchymal transition, metastatic dissemination, and therapeutic resistance. Accordingly, GPC1-targeted therapeutic strategies have been investigated in clinical and preclinical studies. However, clinical efficacy has been limited. We previously developed an anti-GPC1 monoclonal antibody (mAb), G1Mab-28 (mouse IgG1, κ), which exhibits high affinity and specificity for GPC1. In the present study, we generated recombinant isotype-converted G1Mab-28, including G1Mab-28-mG2a (mouse IgG2a) and G1Mab-28-hG1 (human IgG1). Both mAbs recognized GPC1-expressing human tumor cell lines, including lung squamous cell carcinoma PC-10 and pancreatic ductal adenocarcinoma PK-45H, by flow cytometry. Moreover, both mAbs exerted antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against those cell lines. In mouse xenograft models, treatment with the mAbs resulted in potent antitumor efficacy against PC-10 and PK-45H tumors. Collectively, these findings support the therapeutic potential of G1Mab-28 for the treatment of GPC1-positive tumors.
Antitumor Activities of Chimeric Anti-EphA2 Antibodies in Xenograft Models of Breast, Pancreatic, and Colorectal Cancers 国際誌

Guanjie Li, Hiroyuki Suzuki, Tomokazu Ohishi, Hiroyuki Satofuka, Kenichiro Ishikawa, Kai Shimizu, Airi Nomura, Haruto Araki, Naoki Kojo, Kaito Suzuki, Saori Handa, Takuro Nakamura, Miyuki Yanaka, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato

International Journal of Molecular Sciences　27　(7)　2026年4月2日

DOI： 10.3390/ijms27073221 　

詳細を見る詳細を閉じる

Erythropoietin-producing hepatocellular receptor A2 (EphA2) has emerged as a key mediator that promotes tumor malignant progression. EphA2 overexpression and its non-canonical signaling lead to oncogenic transformation, metabolic reprogramming, resistance to treatments, and metastasis. Therefore, strategies targeting EphA2 have been evaluated in clinical trials. However, the clinical effects were not sufficient. An anti-EphA2 monoclonal antibody (mAb), Ea2Mab-7 (mouse IgG1, κ), demonstrated high affinity and specificity among Eph receptors. In this study, we produced recombinant class-switched Ea2Mab-7 variants, including Ea2Mab-7-mG2a (mouse IgG2a) and Ea2Mab-7-hG1 (human IgG1). Both Ea2Mab-7-mG2a and Ea2Mab-7-hG1 recognized human triple-negative breast cancer MDA-MB-231, pancreatic cancer MIA PaCa-2, and colorectal cancer HCT-15 in flow cytometry. Furthermore, both Ea2Mab-7-mG2a and Ea2Mab-7-hG1 exerted significant antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against these tumors. In mouse xenograft models of breast, pancreatic, and colorectal cancers, both mAbs demonstrated antitumor activity. These results indicate the potential of Ea2Mab-7 variants for the treatment of EphA2-positive cancers.
Development of a novel anti-human glypican 5 monoclonal antibody (G5Mab-1) for multiple applications 国際誌査読有り

Yu Kaneko, Tomohiro Tanaka, Shiori Fujisawa, Guanjie Li, Hiroyuki Satofuka, Mika K. Kaneko, Hiroyuki Suzuki, Yukinari Kato

Biochemistry and Biophysics Reports　43　102140-102140　2025年9月

DOI： 10.1016/j.bbrep.2025.102140 　

詳細を見る詳細を閉じる

Glypican 5 (GPC5) is a member of heparan sulfate proteoglycans and is anchored to the plasma membrane via glycosylphosphatidylinositol. GPC5 plays an essential role in kidney, limb, and brain development. Furthermore, GPC5 is expressed in some cancers, but whether it functions as a cancer-promoting or -suppressing factor remains unclear. Therefore, the development of versatile and specific anti-GPC5 monoclonal antibodies (mAbs) is desired to clarify the biological and pathological functions of GPC5. In this study, we successfully established an anti-human GPC5 mAb (clone G5Mab-1) using the Cell-Based Immunization and Screening method. G5Mab-1 is capable of using flow cytometric analysis. G5Mab-1 is specifically bound only to GPC5, not to the other GPC family members. The dissociation constant value of G5Mab-1 for GPC5-overexpressed Chinese hamster ovary K-1 (CHO/GPC5) cells was determined as 9.9 × 10-9 M. Furthermore, G5Mab-1 detected GPC5 in Western blot and immunohistochemistry using CHO/GPC5 cells. Therefore, the G5Mab-1 is highly versatile for basic research and is expected to contribute to clinical applications, such as antibody-based therapy and diagnosis of cancer.
Targeting of bowel tissue by fully human antibodies cross-reactive with human and mouse GPA33 antigen. 国際誌

Genki Hichiwa, Abdur Rafique, Asaki Nagashima, Yayan Wang, Kanako Kazuki, Ryohei Ogihara, Muhammad Feisal Jatnika, Ryosuke Shimamoto, Yumi Iwai, Narumi Uno, Hiroyuki Satofuka, Kazuma Tomizuka, Yuji Ito, Yasuhiro Kazuki

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie　189　118336-118336　2025年8月

DOI： 10.1016/j.biopha.2025.118336 　

詳細を見る詳細を閉じる

Monoclonal antibodies are indispensable therapeutic agents for various diseases, including cancer, autoimmune disorders, and infectious diseases. Glycoprotein A33 (GPA33), a cell surface antigen highly expressed in colorectal cancer, provides a compelling therapeutic target; however, the species-specificity of anti-GPA33 antibodies has limited their utility in preclinical models, thus inhibiting their development. Here, we generated and characterized fully human, cross-reactive anti-GPA33 antibodies using phage-display technology with transchromosomic antibody-producing animals. The resulting single-chain variable fragment and single-chain variable fragment crystallizable antibodies exhibited high specificity and affinity for both human and mouse GPA33. In vivo imaging confirmed their targeted retention in mouse intestine, indicating their potential for developing targeted therapeutic approaches. The ability of these antibodies to recognize both human and murine GPA33 enhances their applicability in preclinical models, improving their translation from experimental to clinical applications. These results highlight the feasibility of developing cross-reactive, fully human antibodies and support the advancement of GPA33-targeted diagnostic approaches and the exploration of novel therapeutic strategies for relevant gastrointestinal diseases.
C7Mab-2: A novel monoclonal antibody against mouse CCR7 established by immunization of the extracellular loop domain

Haruto Yamamoto, Hiroyuki Suzuki, Tomohiro Tanaka, Hiroyuki Satofuka, Mika K. Kaneko, Yukinari Kato

Microbes & Immunity　3　(1)　172-172　2025年7月2日
出版者・発行元： AccScience Publishing
DOI： 10.36922/mi025130028 　

ISSN：3041-0886

eISSN：3029-2883

詳細を見る詳細を閉じる

The chemokine receptors possess seven transmembrane helices connected by an extracellular N‐terminal region, three extracellular loops (ECL1&ndash;3), three intracellular loops, and an intracellular C‐terminal region. Specific monoclonal antibodies (mAbs) against chemokine receptors for flow cytometry have been developed using Cell-Based Immunization and Screening, and the N-terminal peptide immunization methods. However, there are few reports on the establishment of anti-chemokine receptor mAbs through immunization with ECL peptides. Here, an anti-mouse C&ndash;C chemokine receptor type 7 (mCCR7) mAb, C7Mab-2 (rat immunoglobulin G2b, kappa), was established through immunization with the ECL3 peptide. C7Mab-2 demonstrated reactivity to mCCR7-overexpressed Chinese hamster ovary-K1 (CHO/mCCR7) cells in flow cytometry, which was inhibited by the ECL3 peptide. C7Mab-2 did not show cross-reactivity with other mouse CC, CXC, CX3C, and XC chemokine receptors. The dissociation constant value of C7Mab-2 was determined to be 2.8 &times; 10&minus;9 M for CHO/mCCR7 cells. Furthermore, C7Mab-2 detected mCCR7 in immunohistochemistry. This strategy could accelerate the development of novel chemokine receptor mAbs with high affinity and specificity.
A novel anti-mouse CXCR1 monoclonal antibody, Cx1Mab-8, demonstrates nanomolar affinity in flow cytometry. 国際誌査読有り

Guanjie Li, Hiroyuki Suzuki, Tomohiro Tanaka, Hiroyuki Satofuka, Mika K Kaneko, Yukinari Kato

Biochemistry and biophysics reports　42　101965-101965　2025年6月

DOI： 10.1016/j.bbrep.2025.101965 　

詳細を見る詳細を閉じる

CXC chemokine receptor 1 (CXCR1) is an important regulator for neutrophil granulocyte activation through binding to the ligand interleukin-8 (IL-8). Upon binding to IL-8, CXCR1 activates downstream signaling, critical for innate and adaptive immune responses. The IL-8-CXCR1 axis also plays an important role in tumor progression, especially in the tumor microenvironment. CXCR1 antagonists or anti-IL-8 monoclonal antibodies (mAbs) have been developed and evaluated in clinical trials for inflammatory diseases and tumors. In this study, we developed novel mAbs for mouse CXCR1 (mCXCR1) using the N-terminal peptide immunization. Among the established anti-mCXCR1 mAbs, Cx1Mab-8 (rat IgG2b, kappa) recognized mCXCR1-overexpressed Chinese hamster ovary-K1 (CHO/mCXCR1) and mCXCR1-overexpressed LN229 (LN229/mCXCR1) by flow cytometry. The dissociation constant (K D) values of Cx1Mab-8 for CHO/mCXCR1 and LN229/mCXCR1 were determined as 4.1 × 10-10 M and 1.5 × 10-9 M, respectively. These results indicated that Cx1Mab-8 is useful for detecting mCXCR1 by flow cytometry with high affinity and could contribute to obtaining the proof of concept in preclinical studies.
Development of a Novel Anti-Mouse CCR7 Monoclonal Antibody C7Mab-2 by Immunization of the Extracellular Loop Domain

Haruto Yamamoto, Hiroyuki Suzuki, Tomohiro Tanaka, Hiroyuki Satofuka, Mika K. Kaneko, Yukinari Kato

2025年3月10日

DOI： 10.20944/preprints202503.0581.v1 　
Development of Novel Anti-Rhinoceros Podoplanin Monoclonal Antibodies for Flow Cytometry, Western Blot, and Immunohistochemistry

Hiroyuki Suzuki, Shiori Fujisawa, Rena Ubukata, Tomohiro Tanaka, Airi Nomura, Keisuke Shinoda, Takuya Nakamura, Hiroyuki Satofuka, Guanjie Li, Mika K. Kaneko, Yukinari Kato

2025年2月13日

DOI： 10.20944/preprints202502.0986.v1 　
Establishment of a Highly-Sensitive and Specific anti-EphB2 Monoclonal Antibody Eb₂Mab-12 for Flow Cytometry

Rena Ubukata, Hiroyuki Suzuki, Miu Hirose, Hiroyuki Satofuka, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato

2025年1月7日

DOI： 10.20944/preprints202406.0704.v2 　
Development of a Novel Anti-Erythropoietin-Producing Hepatocellular Receptor B6 Monoclonal Antibody Eb6Mab-3 for Flow Cytometry 国際誌

Tomohiro Tanaka, Yu Kaneko, Haruto Yamamoto, Guanjie Li, Shiori Fujisawa, Hiroyuki Satofuka, Keisuke Shinoda, Takuya Nakamura, Mika K Kaneko, Hiroyuki Suzuki, Yukinari Kato

Biochemistry and biophysics reports　41　101960-101960　2024年12月16日

DOI： 10.20944/preprints202412.1235.v1 　

詳細を見る詳細を閉じる

Erythropoietin-producing hepatocellular receptor B6 (EphB6) is a member of the largest Eph subfamily of receptor tyrosine kinases. EphB6 is widely expressed in various tissues and regulates cellular homeostasis by interacting with its membrane-bound ephrin ligands and other receptors. EphB6 is involved in cancer pathology despite lacking kinase activity. Developing sensitive monoclonal antibodies (mAbs) for EphB6 has been desired for treatment, diagnosis, and further analysis of EphB6. This study established a novel specific and sensitive anti-human EphB6 mAb clone Eb6Mab-3 (mouse IgG1, kappa) by the Cell-Based Immunization and Screening (CBIS) method. In flow cytometry, Eb6Mab-3 demonstrated reactivity with EphB6-overexpressed Chinese hamster ovary-K1 cells (CHO/EphB6) and endogenously EphB6-expressing DLD-1 colorectal cancer cells. Cross-reactivity of Eb6Mab-3 was not observed. Eb6Mab-3 demonstrated a moderate binding affinity (dissociation constant; K D) for CHO/EphB6 (K D: 2.6 ± 1.0 × 10-8 M) and a high binding affinity for DLD-1 (K D: 3.4 ± 1.3 × 10-9 M). Eb6Mab-3 can detect EphB6 protein in CHO/EphB6 lysate in Western blot. Eb6Mab-3, established by the CBIS method, could be valuable for analyzing the EphB6-associated cellular functions and has potential applications in diagnosis and treatment with specificity and high affinity for cancer cells.
Ea8Mab-9: A Novel Monoclonal Antibody Against Erythropoietin-Producing Hepatocellular Receptor A8 for Flow Cytometry

Tomohiro Tanaka, Haruto Yamamoto, Yu Kaneko, Keisuke Shinoda, Takuya Nakamura, Guanjie Li, Shiori Fujisawa, Hiroyuki Satofuka, Mika K. Kaneko, Hiroyuki Suzuki, Yukinari Kato

2024年12月12日

DOI： 10.20944/preprints202412.1044.v1 　
Establishment of a Highly-sensitive Anti-EphB2 Monoclonal Antibody Eb2Mab-3 for Flow Cytometry

Rena Ubukata, Hiroyuki Suzuki, Miu Hirose, Hiroyuki Satofuka, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato

2024年6月11日

DOI： 10.20944/preprints202406.0704.v1 　
Establishment of an Antibody Specific for AMIGO2 Improves Immunohistochemical Evaluation of Liver Metastases and Clinical Outcomes in Patients with Colorectal Cancer 国際誌査読有り

Keisuke Goto, Mitsuhiko Osaki, Runa Izutsu, Hiroshi Tanaka, Ryo Sasaki, Akimitsu Tanio, Hiroyuki Satofuka, Yasuhiro Kazuki, Manabu Yamamoto, Hiroyuki Kugoh, Hisao Ito, Mitsuo Oshimura, Yoshiyuki Fujiwara, Futoshi Okada

Diagnostic Pathology　17　(1)　16-16　2021年10月5日
出版者・発行元： Research Square Platform LLC
DOI： 10.1186/s13000-021-01176-2 　

詳細を見る詳細を閉じる

<title>Abstract</title> <bold>Instruction</bold>: The human amphoterin-induced gene and open reading frame (AMIGO) was identified as a novel cell adhesion molecule of type I transmembrane protein. AMIGO2 is one of three members of the AMIGO family (AMIGO1, 2, and 3), and the similarity between them is approximately 40% at the amino acid level. We have previously shown that AMIGO2 functions as a driver of liver metastasis. Immunohistochemical analysis of AMIGO2 expression in colorectal cancer (CRC) using a commercially available anti-AMIGO2 mouse monoclonal antibody clone sc-373699 (sc mAb) correlated with liver metastasis and poor prognosis. However, the sc mAb was found to be cross-reactive with all three molecules in the AMIGO family. <bold>Methods</bold>: We generated a rat monoclonal antibody clone rTNK1A0012 (rTNK mAb) for human AMIGO2. The rTNK mAb was used to re-evaluate the association between AMIGO2 expression and liver metastases/clinical outcomes using the same CRC tissue samples previously reported with sc mAb. <bold>Results</bold>: Western blot analysis revealed that a rTNK mAb was identified as being specific for AMIGO2 protein and did not cross-react with AMIGO1 and AMIGO3. The rTNK mAb and sc mAb showed higher AMIGO2 expression, which correlates with a high frequency of liver metastases (65.3% and 47.5%, respectively), while multivariate analysis showed that AMIGO2 expression was an independent prognostic factor for liver metastases (p = 7.930E-10 and p = 1.707E-5). The Kaplan-Meier analyses showed that the rTNK mAb (p = 0.004), but not sc mAb (p = 0.107), predicted worse overall survival in patients with high AMIGO2 expression. The relationship between AMIGO2 expression and poor disease-specific survival showed a higher level of significance for rTNK mAb (p = 0.00004) compared to sc mAb (p = 0.001). <bold>Conclusion</bold>: These results indicate that the developed rTNK1A0012 mAb is an antibody that specifically recognizes AMIGO2 by immunohistochemistry and can be a more reliable and applicable method for the diagnostic detection of liver metastases and worse prognosis in patients with high AMIGO2-expressing CRC.
Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells 国際誌査読有り

Masahiro Uchino, Hiroko Kojima, Kenta Wada, Mika Imada, Fumitoshi Onoda, Hiroyuki Satofuka, Takahiko Utsugi, Yasufumi Murakami

BMC CANCER　10　414-414　2010年8月

DOI： 10.1186/1471-2407-10-414 　

ISSN：1471-2407
Cellular toxicity of cadmium ions and their detoxification by heavy metal-specific plant peptides, phytochelatins, expressed in mammalian cells 国際誌査読有り

M Takagi, H Satofuka, S Amano, H Mizuno, Y Eguchi, K Hirata, K Miyamoto, K Fukui, T Imanaka

JOURNAL OF BIOCHEMISTRY　131　(2)　233-239　2002年2月

ISSN：0021-924X
Apoptotic signal transduction by cadmium ion and detoxification by plant peptides 査読有り

M Takagi, H Satofuka, T Imanaka

BIOLOGICAL SYSTEMS ENGINEERING　830　163-176　2002年

ISSN：0097-6156
Metal-binding properties of phytochelatin-related peptides 査読有り

H Satofuka, T Fukui, M Takagi, H Atomi, T Imanaka

JOURNAL OF INORGANIC BIOCHEMISTRY　86　(2-3)　595-602　2001年9月

DOI： 10.1016/S0162-0134(01)00223-9 　

ISSN：0162-0134
Anti-phytochelatin monoclonal antibody 査読有り

Hiroyuki Satofuka, Satoshi Amano, Toshiaki Fukui, Haruyuki Atomi, Masahiro Takagi & Tadayuki Imanaka

Biotechnology Letters　22　(17)　1423-1428　2000年10月16日

DOI： 10.1023/A:1005673218300 　

ISSN：0141-5492
Rapid method for detection and detoxification of heavy metal ions in water environments using phytochelatin 査読有り

H Satofuka, S Amano, H Atomi, M Takagi, K Hirata, K Miyamoto, T Imanaka

JOURNAL OF BIOSCIENCE AND BIOENGINEERING　88　(3)　287-292　1999年9月

DOI： 10.1016/S1389-1723(00)80011-0 　

ISSN：1389-1723

︎全件表示 ︎最初の5件までを表示

MISC 30

染色体工学技術による完全ヒト抗体産生動物を用いた腸組織指向性抗体-腸AcuumBodyの開発とIBD治療への応用

飛知和弦輝, WANG Yayan, 飛知和弦輝, WANG Yayan, 荻原諒平, 香月加奈子, 永島明咲, MUHAMMAD Jatnika Feisal, 岩井優実, 嶋本亮輔, 本多英嗣, 宇野佳奈, 里深博幸, ABDUR Rafique, 宇野愛海, 冨塚一磨, 伊東祐二, 香月康宏, 香月康宏, 香月康宏, 香月康宏

Journal of Toxicological Sciences (Web)　50　(Supplement 1)　2025年

ISSN： 1880-3989
染色体工学技術の抗体研究への応用(1)腸組織指向性を有する完全ヒト抗体の創出と基盤的解析

飛知和弦輝, 飛知和弦輝, 飛知和弦輝, RAFIQUE Abdur, 永島明咲, WANG Yayan, WANG Yayan, 香月加奈子, 荻原諒平, 本多英嗣, 宇野佳奈, MUHAMMAD Feisal Jatnika, 嶋本亮輔, 岩井優実, 宇野愛海, 里深博幸, 冨塚一磨, 伊東祐二, 香月康宏, 香月康宏, 香月康宏, 香月康宏

日本抗体学会学術大会プログラム・抄録集(Web)　4th　2025年
完全ヒト抗体産生動物×ファージディスプレイによる腸AccumBody作製と複合バイオロジクスへの応用

飛知和弦輝, 飛知和弦輝, 岩井優実, 永島明咲, 嶋本亮輔, WANG Yayan, WANG Yayan, 荻原諒平, 香月加奈子, 本多英嗣, 宇野佳奈, 宇野愛海, RAFIQUE Abdur, 里深博幸, 冨塚一磨, 伊東祐二, 香月康宏, 香月康宏, 香月康宏, 香月康宏

日本実験動物学会総会講演要旨集(Web)　71st　2024年
染色体工学技術の抗体研究への応用(3)治療応用可能な腸AccumBodyの単離とその性状解析

飛知和弦輝, 飛知和弦輝, RAFIQUE Abdur, 永島明咲, WANG Yayan, WANG Yayan, 荻原諒平, 香月加奈子, 本多英嗣, 宇野佳奈, 嶋本亮輔, 岩井優実, 宇野愛海, 里深博幸, 冨塚一磨, 伊東祐二, 香月康宏, 香月康宏, 香月康宏

日本抗体学会学術大会プログラム・抄録集(Web)　3rd　2024年
染色体工学技術の抗体研究への応用(4)完全ヒト抗体産生動物×ファージディスプレイ法による腸組織移行性抗体の獲得および次世代抗体医薬品への応用

飛知和弦輝, 飛知和弦輝, 嶋本亮輔, 岩井優実, 西田昂平, 永島明咲, JATNIKA Feisal, WANG Yayan, WANG Yayan, 荻原諒平, 高島海, 高島海, 香月加奈子, 本多英嗣, 宇野佳奈, 宇野愛海, RAFIQUE Abdur, 里深博幸, 冨塚一磨, 香月康宏, 香月康宏, 香月康宏, 伊東祐二

日本抗体学会学術大会プログラム・抄録集(Web)　2nd　2023年
染色体工学技術応用(14):完全ヒト抗体産生ラットの抗体およびB細胞産生の解析

森脇崇史, 森脇崇史, 里深博幸, 阿部智志, 岡田茜, 香月加奈子, 濱道修生, 香月康宏, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　46th　2023年
抗体部位特異的修飾技術CCAP,tCAP法による多機能性抗体医薬染色体工学技術の抗体研究への応用(9)mammalian display法による抗SARS-Cov-2合成ヒトポリクローナル抗体取得

安倍麻莉奈, 福島隆斗, 石津由紀, 宇野愛海, 平塚正治, 下谷和人, 森脇崇史, 里深博幸, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 末次正幸, 冨塚一磨

日本抗体学会学術大会プログラム・抄録集(Web)　2nd　2023年
染色体工学技術の抗体研究への応用(10)Mammalian display法による抗SARS-CoV-2合成ヒトモノクローナル抗体取得法の開発

宇野愛海, 安倍麻莉奈, 福島隆斗, 石津由紀, 冨塚一磨, 平塚正治, 下谷和人, 森脇崇史, 里深博幸, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 末次正幸

日本抗体学会学術大会プログラム・抄録集(Web)　2nd　2023年
染色体工学技術応用(4):ミクロセル直接注入によるトランスクロモソミックマウス作出

水谷英二, 里深博幸, 山崎匡太郎, 遠藤猛, 松岡美伶, 岡田茜, 香月康宏, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　46th　2023年
染色体工学技術の抗体研究への応用(2)完全ヒト抗体産生ラット(TC-mAbラット)の作製と抗体レパトアの解析

里深博幸, 森脇崇史, 阿部智志, 岡田茜, 香月加奈子, 濱道修生, 香月康宏, 香月康宏

日本抗体学会学術大会プログラム・抄録集(Web)　1st　2022年
染色体工学技術の抗体研究への応用(11)完全ヒト抗体産生マウスを用いた迅速なヒト抗体作製技術の開発

下谷和人, 濱道修生, 里深博幸, 大安知里, 遠藤猛, 金澤伊織, 森本佳世子, 高山悠, 嵩原昇子, 押村光雄, 富塚一磨, 香月康宏, 香月康宏

日本抗体学会学術大会プログラム・抄録集(Web)　1st　2022年
染色体工学技術応用(1):染色体分配機構や分裂期チェックポイントの阻害剤を用いたCHO細胞での微小核形成の効率化と染色体導入効率の改善

宇野愛海, 里深博幸, 宮本人丸, 本間和久, 鈴木輝彦, 山崎匡太郎, 伊東涼太, 森脇崇史, 冨塚一磨, 押村光雄, 香月康宏, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　45th　2022年
染色体工学技術を用いたがん治療戦略

久郷裕之, 里深博幸, 大平崇人, 大平崇人, 平塚正治, 平塚正治, 香月加奈子, 森脇崇史, 森脇崇史, 香月康宏, 香月康宏

日本がん転移学会学術集会・総会プログラム抄録集　30th　2021年
染色体工学技術応用(19):ヒトiPS細胞を染色体供与細胞としてヒト細胞株へ任意染色体を導入するための新規染色体導入法の開発

宮本人丸, 宇野愛海, 黛亮太, 川崎元希, 里深博幸, 冨塚一磨, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　44th　2021年
染色体工学技術応用(16):ヒト人工染色体(HAC)を用いた高機能化間葉系幹細胞医薬のデザイン

小野寺千紘, 宮崎夏美, 宇野愛海, 山内玲奈, 山内玲奈, 石津由紀, 若狭由布子, 黛亮太, 里深博幸, 香月康宏, 香月康宏, 冨塚一磨

日本分子生物学会年会プログラム・要旨集(Web)　44th　2021年
染色体工学技術応用(13):抗体の表現型スクリーニングを可能にする,多様化誘導型抗体発現細胞ライブラリの開発

橋本七海, 笹川航, 宇野愛海, 里深博幸, 香月康宏, 香月康宏, 堀田秋津, 冨塚一磨

日本分子生物学会年会プログラム・要旨集(Web)　44th　2021年
ファージディスプレイ法を用いた完全ヒト抗体ライブラリからの新規乳がん標的分子の探索

飛知和弦輝, 里深博幸, 押村光雄, RAFIQUE Abdur, 伊東祐二, 香月康宏, 香月康宏

日本がん転移学会学術集会・総会プログラム抄録集　30th　2021年
染色体工学技術応用(9):完全ヒト抗体産生動物から得た末梢血単球細胞からの抗原特異的な抗体作製

下谷和人, 下谷和人, 里深博幸, 貞包和樹, 貞包和樹, 飛知和弦輝, 飛知和弦輝, 香月康宏, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　44th　2021年
染色体工学技術応用(10):タンパク質プローブを用いた簡便なモノクローナル抗体取得技術の構築

貞包和樹, 里深博幸, 田中博志, 田中満里愛, 森本佳世子, 下谷和人, 飛知和弦輝, 栗原靖之, 押村光雄, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　44th　2021年
抗EpCAM完全ヒト抗体をモデルとした抗体-薬剤複合体開発に適したスクリーニング方法の比較

WANG Yayan, WANG Yayan, 里深博幸, 山崎匡太郎, 三宅直美, 福原武志, 押村光雄, XU Gao, 香月康宏, 香月康宏

日本がん転移学会学術集会・総会プログラム抄録集　30th　2021年
新型コロナウイルスspike蛋白質と中和抗体NT-193複合体のX線結晶構造解析

喜多俊介, 小野寺大志, 安達悠, 森山彩野, 野村尚生, 田所高志, 安楽佑樹, 湯本航平, 田聡, 福原秀雄, 鈴木干城, 佐々木慈英, 福士秀悦, 里深博幸, 香月康宏, 押村光雄, 橋口隆生, 高橋宜聖, 前仲勝実

日本結晶学会年会講演要旨集　2021　2021年
完全ヒト抗体産生動TC-mAbマウスの免疫応答に関する解析

森脇崇史, 里深博幸, 阿部智志, 田中博志, 山崎匡太郎, 飛知和弦輝, 冨塚一磨, 押村光雄, 香月康宏, 香月康宏

日本がん転移学会学術集会・総会プログラム抄録集　30th　2021年
完全ヒト抗体産生マウスを用いた研究(1):ヒト抗体遺伝子全長を搭載した人工染色体を保持するtrans-chromosomicマウスのレパトア解析

里深博幸, 森脇崇史, 森脇崇史, 阿部智志, 田中博志, 森本佳世子, 山崎匡太郎, 冨塚一磨, 押村光雄, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　43rd　2020年
ヒト/マウス人工染色体技術応用(4):生きた細胞内における人工染色体の蛍光標識法

松尾京亮, 里深博幸, 山崎匡太郎, 本間和久, 押村光雄, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　42nd　2019年
ヒト/マウス人工染色体技術応用(12):EpCAMをモデル抗原とした完全ヒト抗体産生マウスの免疫と完全ヒトモノクローナル抗体の作製

山崎匡太郎, 里深博幸, 阿部智志, 森脇崇史, 田中博志, 押村光雄, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　42nd　2019年
ヒト/マウス人工染色体技術応用(11):完全ヒト抗体産生マウスの免疫応答に関する解析

里深博幸, 森脇崇史, 田中博志, 阿部智志, 山崎匡太郎, 富塚一磨, 押村光雄, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　42nd　2019年
ヒト/マウス人工染色体技術応用(13):完全ヒトポリクローナル抗体を用いたがん治療薬の開発

飛知和弦輝, 里深博幸, 押村光雄, 香月康宏, 香月康宏

日本分子生物学会年会プログラム・要旨集(Web)　42nd　2019年
643 ポリペプチドphytochelatinの重金属捕捉に関わる化学構造

里深博幸, 福居俊昭, 跡見晴幸, 高木昌宏, 今中忠行

日本生物工学会大会講演要旨集　13　276-276　2001年
出版者・発行元：日本生物工学会
421 重金属捕捉ペプチドphytochelatin誘導体の機能解析

里深博幸, 福居俊昭, 高木昌宏, 跡見晴幸, 今中忠行

日本生物工学会大会講演要旨集　12　95-95　2000年
出版者・発行元：日本生物工学会
502 抗Phytochelatin抗体の取得と、有害重金属汚染の診断、浄化への応用

里深博幸, 天野智史, 高木昌宏, 跡見晴幸, 今中忠行

日本生物工学会大会講演要旨集　10　49-49　1998年
出版者・発行元：日本生物工学会

︎全件表示 ︎最初の5件までを表示

書籍等出版物 1

臨床免疫･アレルギー科

里深博幸、森脇崇史、阿部智志、香月康宏

科学評論社　2023年4月

産業財産権 15

タンパク質−微粒子複合体、及びそれを用いた標的生体物質の検出方法

里深博幸

産業財産権の種類: 特許権
目的抗原に対する抗体の作製方法

里深博幸, 岡部洋子

産業財産権の種類: 特許権
抗SLC6A6抗体を用いたがん治療用医薬組成物

里深博幸, 岡部洋子, 大瀬賢介, 向畑成樹, 村上康文

産業財産権の種類: 特許権
浸潤能の高い癌細胞の検出用又は診断用試薬

里深博幸, 岡部洋子

産業財産権の種類: 特許権
抗SLC6A6抗体を用いたがん治療用医薬組成物

里深博幸, 大瀬賢介, 向畑成樹, 秋山弘匡, 大津正也, 岡部洋子, 村上康文

産業財産権の種類: 特許権
抗LGR6抗体を含む癌の検出用又は診断用試薬

里深博幸, 村上康文

産業財産権の種類: 特許権
がん治療用医薬組成物

里深博幸, 大瀬賢介, 向畑成紀, 加藤由美子, 岡部洋子, 松村保広, 安永正浩

産業財産権の種類: 特許権
大腸がんマーカーに対する抗体

里深博幸, 岡部洋子, 松村保広, 安永正浩

産業財産権の種類: 特許権
がん細胞を用いた抗体の製造方法

里深博幸, 内野雅浩, 花岡慎悟

産業財産権の種類: 特許権
がん細胞を用いた免疫方法

里深博幸, 内野雅浩, 小島弘子

産業財産権の種類: 特許権
表面プラズモン共鳴による物質の検出方法

里深博幸

産業財産権の種類: 特許権
造血幹細胞の分化抑制又は増殖方法

戸所一雄, 里深博幸, 桑原義和

産業財産権の種類: 特許権
重金属の測定方法および回収方法

今中忠行, 里深博幸, 高木昌宏

産業財産権の種類: 特許権
がん治療用医薬組成物

里深博幸, 大瀬賢介, 向畑成紀, 加藤由美子, 岡部洋子, 松村保広, 安永正浩

特許第5747283号

産業財産権の種類: 特許権
がん細胞を用いた免疫方法

里深博幸, 内野雅浩, 小島弘子

特許第5688699号

産業財産権の種類: 特許権

︎全件表示 ︎最初の5件までを表示

共同研究・競争的資金等の研究課題 1

ヒト抗体産生モデルマウスを用いたウイルス感染に対抗するヒト中和抗体の多様性解析

里深博幸

提供機関：Japan Society for the Promotion of Science

制度名：Grants-in-Aid for Scientific Research

研究種目：Grant-in-Aid for Scientific Research (C)

研究機関：Tohoku University

2024年4月1日～ 2027年3月31日